Moreover, low serum levels of soluble MAdCAM-1 were correlated with poor prognosis in independent cohorts of lung, kidney, and bladder cancer patients, suggesting that the MAdCAM-1–α4β7 axis could be a targetable gut immune checkpoint in cancer immunosurveillance. This evidence concerns the gene MADCAM1 and urinary bladder carcinoma.